Moderna Inc. plans to develop and begin testing vaccines targeting 15 of the world’s most worrisome pathogens by 2025 and will permanently waive the company’s COVID-19 vaccine patents for shots intended for certain low-income and middle-income countries.
Research Roundup: Nanotherapy and Islet Transplants for Diabetes and MoreBusiness, Clinical Trials, Coronavirus Disease 2019 (COVID-19), Diabetes, DNA, Drug Delivery, Immunosuppressants, Islet cells, Messenger RNA (mRNA) Vaccines, Nature Nanotechnology, Northwestern University, R&D, San Diego (UCSD), San Francisco (UCSF), Transplants, Type 1 Diabetes, Viral Infections
Researchers have been working to develop approaches to curing Type 1 diabetes by transplanting healthy islet cells into the pancreas. Investigators at Northwestern University have developed a technique to make the immunomodulation effect of immunosuppressive drugs more effective.
Shares of Verrica Pharmaceuticals plunged after the company received a Complete Response Letter from the U.S. Food and Drug Administration for an experimental treatment for molluscum contagiosum (molluscum).
Moderna Chief Executive Officer Stéphane Bancel sees significant growth opportunities for his company and messenger RNA-based vaccines.
The U.S. Food and Drug Administration accepted for Priority Review Pfizer Inc.’s Biologics License Application for TicoVac, the company’s tick-borne encephalitis vaccine for active immunization to prevent TBE in individuals 1 year of age and older.
AbbVie and Harvard University entered into a $30 million collaborative research alliance to develop therapies against emergent viral infections, with a focus on those caused by coronaviruses and by viruses that lead to hemorrhagic fever.
Biopharma Industry News: Update on the Novel Coronavirus3D, Antivirals, Business, Clinical Trials, Coronavirus Disease (COVID-19) Pandemic, FDA, FDA/Regulatory, Genomics, Laboratory, MERS, Messenger RNA (mRNA) Vaccines, Partnerships, Plasma, R&D, SARS, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Tests
A summary of daily biopharma industry news regarding the novel coronavirus trending on March 27, 2020, with the FDA now working with 220 test developers.
Verrica Pharmaceuticals Inc. submitted a New Drug Application to the U.S. Food and Drug Administration for VP-102 (cantharidin 0.7% topical solution) for the treatment of molluscum contagiosum.
The U.S. Food and Drug Administration approved Fera’s New Drug Application for Avaclyr (acyclovir ophthalmic ointment) 3% for the treatment of herpetic keratitis.
Japan scientists win backing for work on potential Nipah vaccineBat-Borne Diseases, Brain Damage, Coalition for Epidemic Preparedness Innovations (CEPI), Crimean-Congo hemorrhagic fever (CCHF), Deals, Ebola, Epidemics, Genes, India, Lassa Virus, Measles, MERS, Nipah Virus, Outbreaks, R&D, Vaccines, World Health Organization, Zika Virus
A global coalition set up to fight emerging epidemics struck a $31 million deal with scientists at Japan’s University of Tokyo to speed up work on a vaccine against a brain-damaging disease caused by the Nipah virus.